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Blood substitutes have long been sought after, and artifi-
cial oxygen carriers may soon become a reality. Despite
increased safety of allogeneic blood in terms of transmis-
sion of infectious diseases [1], avoiding allogeneic blood
transfusions remains an important goal in perioperative
and intensive care medicine. This is because allogeneic
blood transfusions may cause immunosuppression with an
increased incidence of postoperative infections [2,3] and
may adversely affect outcome in intensive care [4], and
thus they remain a public concern [5].
Artificial oxygen carriers are promising substances to avoid
allogeneic blood transfusions and related side effects. In
addition, artificial oxygen carriers may be effective anti-
ischaemic agents in a variety of diseases and conditions
that are characterized by compromised tissue oxygena-
tion. Artificial oxygen carriers may be grouped into
haemoglobin-based oxygen carriers (HBOCs) and perfluo-
rocarbon emulsions. The biological efficacy of both
groups has been documented in a variety of animal exper-
iments [6,7], and phase III trials are ongoing at present to
prove their clinical efficacy.
In HBOCs (see article by Baron J-F, this issue of Critical
Care), the haemoglobin is either human (outdated human
blood), bovine or from a genetically engineered source [7].
All haemoglobin solutions tested contain modified
haemoglobin to improve oxygen off-loading, by decreas-
ing oxygen affinity, and to reduce side effects. At present,
haemoglobin solutions in clinical trials are aqueous solu-
tions, but the production of micro-encapsulated haemo-
globin particles (neo red cells) might be a future option
[8,9]. Comparison between HBOCs is difficult because
there are very few studies that directly compare different
products. It appears though that larger haemoglobin mole-
cules, in particular haemoglobin polymers with a small
residual haemoglobin monomer fraction, are better toler-
ated; this is probably due to a reduced penetration of
these relatively large molecules into the vessel wall [10].
In the group of perfluorocarbon emulsions, only perflubron
emulsion is in phase III testing. It has been shown recently
that treatment with perflubron emulsion in conjunction
with pure oxygen ventilation was more effective than
retransfusion of autologous blood in reversing physiologic
transfusion triggers [11]. With perflubron emulsion patients
thus may tolerate lower haemoglobin levels, and perflubron
emulsion may be used to modify the acute normovolemic
haemodilution (ANH) into ‘augmented ANH’ (see article
by Spahn DR, this issue of Critical Care). In this way, the
added oxygen unloading capacity of the perflubron emul-
sion is utilized to compensate very low intraoperative
haemoglobin values. Because of retransfusion of the ANH
blood at the end of the procedure, the patient’s are sup-
ported by their own blood in the postoperative period.
Comparing HBOCs and perfluorocarbon emulsions is diffi-
cult. First, there are no studies that directly compare the
two groups of artificial oxygen carriers. Second, the practi-
cal use of these substances will be relatively different once
they are on the market. Haemoglobin solutions might be
used relatively similar to a conventional blood transfusion
and haemoglobin measurement may still be used to assess
the oxygen transport capacity. When used to avoid allo-
geneic blood transfusions, perfluorocarbon emulsions will
be used preferentially in the concept of ‘augmented
ANH’, and physiologic transfusion triggers [12] will be
used primarily to assess the adequacy of oxygen delivery.
Despite a longer than expected final development phase,
HBOCs as well as perfluorocarbon emulsions will eventu-
ally be released for general clinical use and will substan-
tially alter standard clinical practice.
References
1. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP: Transfusion
medicine. First of two parts – blood transfusion. N Engl J Med
1999, 340:438–447.
2. Spahn DR, Leone BJ, Reves JG, Pasch T: Cardiovascular and coro-
nary physiology of acute isovolemic hemodilution: a review of
nonoxygen-carrying and oxygen-carrying solutions. Anesth Analg
1994; 78:1000–1021.
3. Spahn DR, Schmid ER: Haemodilution in cardiac and vascular
surgery. Curr Opin Anaesthesiol 1996; 9:54–61.
HBOC = haemoglobin-based oxygen carrier; ANH = acute normovolemic haemodilution.4. Hebert PC, Wells G, Blajchman MA, et al, and the Transfusion
Requirements in Critical Care Investigators for the Canadien Critical
Care Trials Group: A multicenter, randomized, controlled clinical
trial of transfusion requirements in critical care. N Engl J Med
1999;  340:409–417.
5. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP: Transfusion
medicine. Second of two parts – blood conservation. N Engl J Med
1999; 340:525–533.
6. Keipert PE: Perfluorochemical emulsions: future alternatives to
transfusion. Blood Subst Princ Meth Prod Clin Trials 1998; 2:
127–156.
7. Frietsch T, Lenz C, Waschke KF: Artificial oxygen carriers. Eur J
Anaesth 1998;  15:571–584.
8. Chang TM: Artificial cells with emphasis on cell encapsulation of
genetically engineered cells. Artif Organs 1998; 22:958–965.
9. Chang TM: Modified hemoglobin-based blood substitutes:
crosslinked, recombinant and encapsulated hemoglobin. Vox
Sang 1998; 74 (suppl 2):233–241.
10. Gould SA, Moss GS: Clinical development of human polymerized
hemoglobin as a blood substitute. World J Surg 1996; 20:
1200–1207.
11. Spahn DR, van Bremt R, Theilmeier G, et al, Perflubron Emulsion
Study Group: Perflubron emulsion delays blood transfusion in
orthopedic surgery. Anesthesiology 1999, in press.
12. A Report by the American Society of Anesthesiologists Task Force on
Blood Component Therapy: Practice guidelines for blood compo-
nent therapy. Anesthesiology 1996; 84:732–747.
R92 Critical Care 1999, Vol 3 No 5